Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 May;53(9):1048-1049.
doi: 10.1111/apt.16323.

Letter: tenofovir may be superior to entecavir for treatment-naïve chronic hepatitis B patients

Affiliations
Comment

Letter: tenofovir may be superior to entecavir for treatment-naïve chronic hepatitis B patients

Ji-Gan Wang et al. Aliment Pharmacol Ther. 2021 May.
No abstract available

PubMed Disclaimer

Comment in

Comment on

References

REFERENCES

    1. Pol S, ANRS AFEF study group. Similar 5-year HCC occurrence in Tenofovir- and Entecavir-treated HBV chronic infection in the French AFEF/ANRS CO22 Hepather cohort. Aliment Pharmacol Ther. 2021;53:616-629.
    1. Teng YX, Li MJ, Xiang BD, Zhong JH. Tenofovir may be superior to entecavir for preventing hepatocellular carcinoma and mortality in individuals chronically infected with HBV: a meta-analysis. Gut. 2020;69:1900-1902.
    1. Choi WM, Choi J, Lim YS. Effects of tenofovir vs entecavir on risk of hepatocellular carcinoma in patients with chronic HBV infection: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2021;19:246-258.e9.
    1. Iloeje UH, Yang H, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130:678-686.
    1. Chen G, Lin W, Shen F, Iloeje UH, London WT, Evans AA. Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am J Gastroenterol. 2006;101:1797-1803.

MeSH terms

LinkOut - more resources